reports
Des institutions mondiales de renom et IBA lancent la Proton Therapy A...
Des institutions mondiales de renom et IBA lancent la Proton Therapy Academy pour élaborer l'avenir des soins contre le cancer Nouvelle initiative mondiale de formation présentée lors de la conférence annuelle PTCOG 2025 Louvain-la-Neuve, Belgique, le 4 juin 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui le lancement de la Proton Therapy Academy, une nouvelle initiative de formation et d’éducation développée en parte...
World's Leading Institutions and IBA launch Proton Therapy Academy to ...
World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has be...
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Confe...
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the w...
Iba – Acquisition of Own Shares - Completion of the Share Buyback Prog...
Iba – Acquisition of Own Shares - Completion of the Share Buyback Program Immediate Release – May 30th, 2025 Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until Decembe...
IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACT...
IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACTIONS Publication immédiate – 30 mai 2025 Louvain-la-Neuve, Belgique, 30 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'...
argenx Announces Results of Annual General Meeting of Shareholders
argenx Announces Results of Annual General Meeting of Shareholders May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025. 91.1% of the Company’s share capital was represented at the Annual General Meeting. All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This age...
Iba – Acquisition of Own Shares
Iba – Acquisition of Own Shares Immediate Release – May 26th, 2025 Louvain-la-Neuve, Belgium, May 26th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 26 mai 2025 Louvain-la-Neuve, Belgique, 26 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décembre ...
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Solid 1Q25. Ascencio: Resilient results. Gimv: NAV a tad higher than expected, underlying companies surprisingly strong. IBA: Soft start in Technologies, 2025 and 2028 guidance reiterated. OCI: In-line 1Q25 trading update. Vopak: IPO of AVTL - value coming to the surface
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Hoste
- Wim Lewi
IBA Business Update Q1 2025
IBA Business Update Q1 2025 Year starting on track Louvain-la-Neuve, Belgium, 22 May 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter of 2025. Group Overview Solid commercial momentum, particularly in IBA Clinical Equipment and Services backlog at €1.5 billion, with conversion executed in line with plan€ 9 million1 positive net cash position, decreasing vs. year-end. Foreseen backlog delivery activities impacting inventory and contract in progress build-up. New ventures (IBA Investme...
IBA déclaration intermédiaire - premier trimestre 2025
IBA déclaration intermédiaire - premier trimestre 2025 Début d’année conforme aux attentes Louvain-la-Neuve, Belgique, le 22 mai 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le premier trimestre se terminant le 31 mars 2025. Vue d'ensemble des activités du Groupe Solide dynamique commerciale, en particulier pour l’entité IBA ClinicalCarnet de commandes d'équipements et de services à 1,5 milliard d'euros, dont la conversion évolue comme prévuPosition de trésorerie net...
- Guy Sips
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
Argen X SE: 1 director
A director at Argen X SE bought 1,527 shares at 479.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiw...
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan The Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Ph...
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone...
IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone® IKON à Taiwan Le Cyclone® IKON est le cyclotron haute énergie et haute capacité d'IBA qui offre le plus grand spectre d'énergie pour la production d’isotopes TEP et TEMP de 13 MeV à 30 MeV. Louvain-la-Neuve, Belgique, le 21 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de radiopharmaceutiques, annonce avoir signé un contrat avec PET Pharm Bio pour installer un centre de production d'isotopes...
IBA – ACQUISITION OF OWN SHARES
IBA – ACQUISITION OF OWN SHARES Immediate Release – May 19th, 2025 Louvain-la-Neuve, Belgium, May 19th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March ...
IBA – ACQUISITION D’ACTIONS PROPRES
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 19 mai 2025 Louvain-la-Neuve, Belgique, 19 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décembr...
IBA launches CASSY®, a new compact radiochemistry module to enhance ef...
IBA launches CASSY®, a new compact radiochemistry module to enhance efficiency in radiopharmaceuticals production Louvain-La-Neuve, Belgium, 13 May 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announces the launch of CASSY®, a compact synthesizer designed to streamline radiopharmaceutical production processes. This new IBA solution is set to transform the way radiometals and radiotracers are produced. CASSY®, Compact Automated Scalable SYnthesis, enhanc...
IBA lance CASSY®, un nouveau module compact de radiochimie pour amélio...
IBA lance CASSY®, un nouveau module compact de radiochimie pour améliorer l'efficacité de la production de radiopharmaceutiques Louvain-la-Neuve, Belgique, le 13 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de radiopharmaceutiques, annonce le lancement de CASSY®, un synthétiseur compact conçu pour rationaliser les processus de production de radiopharmaceutiques. Cette nouvelle solution IBA est destinée à transformer la manière dont les radiotraceurs et les radio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.